We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Inspire (INSP) Up 7.5% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Inspire Medical Systems (INSP - Free Report) . Shares have added about 7.5% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Inspire due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Inspire Medical Systems, Inc. before we dive into how investors and analysts have reacted as of late.
Inspire Medical delivered an earnings per share of 45 cents in second-quarter 2025, up 40.6% year over year. The figure topped the Zacks Consensus Estimate by 104.6%.
INSP’s Revenues in Detail
Inspire Medical registered revenues of $217.1 million in the second quarter, up 10.8% year over year. The figure beat the Zacks Consensus Estimate by 0.9%.
Per management, the overall revenue growth was primarily driven by increased market penetration and increased physician and patient awareness of the Inspire system. However, this was partially offset by ENT surgeon capacity constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.
Inspire Medical’s Segment Details
Inspire Medical’s operations consist of two geographic regions — the United States and All other countries.
In the quarter under review, U.S. revenues of $207.2 million reflected an increase of 10.3% from the year-ago quarter on a reported basis.
As of June 30, 2025, Inspire Medical had 348 U.S. sales territories and 259 field clinical representatives compared with 335 and 230, respectively, as of Dec. 31, 2024.
Revenues from All other countries totaled $9.9 million, up 23% year over year on a reported basis.
INSP’s Margin Analysis
In the second quarter, Inspire Medical’s gross profit increased 9.9% year over year to $182.4 million. However, the gross margin contracted 74 basis points (bps) to 84%.
SG&A expenses jumped 20.8% year over year to $159.5 million. Research and development expenses decreased 9.2% year over year to $26.2 million. Operating expenses of $185.7 million increased 15.4% year over year.
Operating loss totaled $3.3 million against the prior-year quarter’s operating profit of $5.1 million.
Inspire Medical’s Financial Position
Inspire Medical exited second-quarter 2025 with cash and cash equivalents and short-term investments of $300.9 million compared with $369.2 million at the first-quarter end.
Cumulative net cash used in operating activities at the end of second-quarter 2025 was $4 million, against net cash provided by operating activities of $8.8 million a year ago.
INSP’s Outlook
Inspire Medical has lowered its revenue and earnings per share outlook for 2025.
The company now projects revenues in the range of $900 million-$910 million (representing growth of 12-13% from 2024 levels), lowered from the prior outlook of $940 million-$955 million (representing growth of 17-19% from 2024 levels). The Zacks Consensus Estimate is pegged at $949.1 million.
Inspire Medical now expects its earnings per share for 2025 to be between 40 cents and 50 cents, lowered from the prior outlook of $2.20-$2.30. The Zacks Consensus Estimate is pegged at $2.26.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -118.76% due to these changes.
VGM Scores
At this time, Inspire has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Inspire has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Inspire is part of the Zacks Medical Info Systems industry. Over the past month, Omnicell (OMCL - Free Report) , a stock from the same industry, has gained 5.3%. The company reported its results for the quarter ended June 2025 more than a month ago.
Omnicell reported revenues of $290.56 million in the last reported quarter, representing a year-over-year change of +5%. EPS of $0.45 for the same period compares with $0.51 a year ago.
Omnicell is expected to post earnings of $0.36 per share for the current quarter, representing a year-over-year change of -35.7%. Over the last 30 days, the Zacks Consensus Estimate has changed +50%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Omnicell. Also, the stock has a VGM Score of A.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Inspire (INSP) Up 7.5% Since Last Earnings Report?
A month has gone by since the last earnings report for Inspire Medical Systems (INSP - Free Report) . Shares have added about 7.5% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Inspire due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Inspire Medical Systems, Inc. before we dive into how investors and analysts have reacted as of late.
INSP Q2 Earnings Beat Estimates, Gross Margin Contracts
Inspire Medical delivered an earnings per share of 45 cents in second-quarter 2025, up 40.6% year over year. The figure topped the Zacks Consensus Estimate by 104.6%.
INSP’s Revenues in Detail
Inspire Medical registered revenues of $217.1 million in the second quarter, up 10.8% year over year. The figure beat the Zacks Consensus Estimate by 0.9%.
Per management, the overall revenue growth was primarily driven by increased market penetration and increased physician and patient awareness of the Inspire system. However, this was partially offset by ENT surgeon capacity constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications.
Inspire Medical’s Segment Details
Inspire Medical’s operations consist of two geographic regions — the United States and All other countries.
In the quarter under review, U.S. revenues of $207.2 million reflected an increase of 10.3% from the year-ago quarter on a reported basis.
As of June 30, 2025, Inspire Medical had 348 U.S. sales territories and 259 field clinical representatives compared with 335 and 230, respectively, as of Dec. 31, 2024.
Revenues from All other countries totaled $9.9 million, up 23% year over year on a reported basis.
INSP’s Margin Analysis
In the second quarter, Inspire Medical’s gross profit increased 9.9% year over year to $182.4 million. However, the gross margin contracted 74 basis points (bps) to 84%.
SG&A expenses jumped 20.8% year over year to $159.5 million. Research and development expenses decreased 9.2% year over year to $26.2 million. Operating expenses of $185.7 million increased 15.4% year over year.
Operating loss totaled $3.3 million against the prior-year quarter’s operating profit of $5.1 million.
Inspire Medical’s Financial Position
Inspire Medical exited second-quarter 2025 with cash and cash equivalents and short-term investments of $300.9 million compared with $369.2 million at the first-quarter end.
Cumulative net cash used in operating activities at the end of second-quarter 2025 was $4 million, against net cash provided by operating activities of $8.8 million a year ago.
INSP’s Outlook
Inspire Medical has lowered its revenue and earnings per share outlook for 2025.
The company now projects revenues in the range of $900 million-$910 million (representing growth of 12-13% from 2024 levels), lowered from the prior outlook of $940 million-$955 million (representing growth of 17-19% from 2024 levels). The Zacks Consensus Estimate is pegged at $949.1 million.
Inspire Medical now expects its earnings per share for 2025 to be between 40 cents and 50 cents, lowered from the prior outlook of $2.20-$2.30. The Zacks Consensus Estimate is pegged at $2.26.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month.
The consensus estimate has shifted -118.76% due to these changes.
VGM Scores
At this time, Inspire has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Inspire has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Inspire is part of the Zacks Medical Info Systems industry. Over the past month, Omnicell (OMCL - Free Report) , a stock from the same industry, has gained 5.3%. The company reported its results for the quarter ended June 2025 more than a month ago.
Omnicell reported revenues of $290.56 million in the last reported quarter, representing a year-over-year change of +5%. EPS of $0.45 for the same period compares with $0.51 a year ago.
Omnicell is expected to post earnings of $0.36 per share for the current quarter, representing a year-over-year change of -35.7%. Over the last 30 days, the Zacks Consensus Estimate has changed +50%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Omnicell. Also, the stock has a VGM Score of A.